CONTENTS

8 FORECAST: ISCHEMIC STROKE (Published on 02 July 2018)
8 OVERVIEW
9 MARKET OVERVIEW AND TRENDS
13 MARKET DEFINITION AND METHODOLOGY
19 PRIMARY RESEARCH METHODOLOGY
21 BIBLIOGRAPHY
22 PRODUCT PROFILE: ASPIRIN
28 PRODUCT PROFILE: PLAVIX

41 TREATMENT: ISCHEMIC STROKE (Published on 14 December 2016)
41 OVERVIEW
42 EXECUTIVE SUMMARY
43 PRIMARY RESEARCH METHODOLOGY
45 DISEASE DEFINITION AND DIAGNOSIS
55 CURRENT TREATMENT OPTIONS
59 PRESCRIBING TRENDS

72 EPIDEMIOLOGY: STROKE (Published on 07 January 2019)
72 OVERVIEW
74 DISEASE BACKGROUND
77 METHODOLOGY
86 FORECAST
103 BIBLIOGRAPHY
107 APPENDIX: ADDITIONAL SOURCES

109 MARKETED DRUGS: ISCHEMIC STROKE (Published on 02 July 2018)
109 OVERVIEW
110 EXECUTIVE SUMMARY
111 PRODUCT OVERVIEW
113 PRODUCT PROFILE: ACTIVASE
122 PRODUCT PROFILE: AGGRENOX
130 PRODUCT PROFILE: ASPIRIN
136 PRODUCT PROFILE: PLAVIX

149 PIPELINE: ISCHEMIC STROKE (Published on 02 July 2018)
149 OVERVIEW
150 EXECUTIVE SUMMARY
151 CLINICAL PIPELINE OVERVIEW
152 RECENTLY DISCONTINUED DRUGS
162 ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES

LIST OF FIGURES
10 Figure 1: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by country, 2016–25
11 Figure 2: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by drug, 2016–25
15 Figure 3: Patient-based forecast methodology for ischemic stroke
17 Figure 4: Price sources and calculations, by country
22 Figure 5: Datamonitor Healthcare’s drug assessment summary of Aspirin for ischemic stroke
23 Figure 6: Datamonitor Healthcare’s drug assessment summary of Aspirin for ischemic stroke
25 Figure 7: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
34 Figure 8: Plavix for ischemic stroke – SWOT analysis
35 Figure 9: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
36 Figure 10: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
38 Figure 11: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
52 Figure 12: Mean percentage of patients presenting with stroke-like symptoms diagnosed with particular indications, by country, 2015
59 Figure 13: Mean percentage of ischemic stroke patients receiving each treatment regimen in the US, Japan, and five major EU markets, by country, 2015
61 Figure 14: Mean percentage of ischemic stroke patients receiving each thrombolytic therapy in the US, Japan, and five majorEU  markets, by country, 2015
63 Figure 15: Mean percentage of ischemic stroke patients receiving each neuroprotective therapy in the US, Japan, and five major EU markets, by country, 2015
65 Figure 16: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the acute treatment setting, by country, 2015
67 Figure 17: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the secondary prevention setting at first-line, by country, 2015
69 Figure 18: Mean percentage of ischemic stroke patients who progress to second-line treatment in the secondary prevention setting, by country, 2015
70 Figure 19: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in secondary prevention setting at second-line, by country, 2015
90 Figure 20: Trends in diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
94 Figure 21: Trends in diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
98 Figure 22: Trend in diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
102 Figure 23: Trends in diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
117 Figure 24: Activase for ischemic stroke – SWOT analysis
118 Figure 25: Datamonitor Healthcare’s drug assessment summary of Activase for ischemic stroke
119 Figure 26: Datamonitor Healthcare’s drug assessment summary of Activase for ischemic stroke
126 Figure 27: Aggrenox for ischemic stroke – SWOT analysis
127 Figure 28: Datamonitor Healthcare’s drug assessment summary of Aggrenox for ischemic stroke
128 Figure 29: Datamonitor Healthcare’s drug assessment summary of Aggrenox for ischemic stroke
130 Figure 30: Datamonitor Healthcare’s drug assessment summary of Aspirin for ischemic stroke
131 Figure 31: Datamonitor Healthcare’s drug assessment summary of Aspirin for ischemic stroke
133 Figure 32: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
142 Figure 33: Plavix for ischemic stroke – SWOT analysis
143 Figure 34: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
144 Figure 35: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
146 Figure 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
12 Table 1: Distribution of total market sales across ischemic stroke subgroups, 2016–25
13 Table 2: Summary of drug classes and molecules included in Datamonitor Healthcare’s ischemic stroke patient-based forecast
13 Table 3: Patent expiries occurring within the ischemic stroke market during the forecast period, 2016–25
18 Table 4: Exchange rates used for calculating prices
19 Table 5: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
26 Table 6: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
29 Table 7: Plavix drug profile
31 Table 8: Plavix pivotal trial data in ischemic stroke
33 Table 9: Plavix ongoing late-phase clinical trials in ischemic stroke
39 Table 10: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
43 Table 11: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
46 Table 12: Overview of risk factors for a first transient ischemic attack or ischemic stroke
49 Table 13: Mean percentage of ischemic stroke patients that have co-morbidities in the US, Japan, and five major EU markets, by country, 2015
50 Table 14: Common transient ischemic attack and ischemic stroke symptoms
51 Table 15: Overview of tests used in ischemic stroke and transient ischemic attack patients, by major category
56 Table 16: Treatments available for ischemic stroke across the US, Japan, and five major EU markets
60 Table 17: Mean percentage of ischemic stroke patients receiving each type of therapy in the US, Japan, and five major EU markets, by country, 2015
62 Table 18: Overview of inclusion and exclusion criteria for patients eligible for alteplase treatment in the US
66 Table 19: Mean percentage of ischemic stroke patients that progress to secondary prevention in the US, Japan, and five major EU markets, by country, 2015
78 Table 20: Sources used for the epidemiological analysis of stroke incidence in the US, Japan, and five major EU markets, by country
81 Table 21: Sources used for the epidemiological analysis of stroke prevalence in the US, Japan, and five major EU markets, by country
87 Table 22: Diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
91 Table 23: Diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
95 Table 24: Diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
99 Table 25: Diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
112 Table 26: Key marketed drugs for ischemic stroke
114 Table 27: Activase drug profile
116 Table 28: Activase pivotal trial data in ischemic stroke
123 Table 29: Aggrenox drug profile
124 Table 30: Aggrenox pivotal trial data in ischemic stroke
125 Table 31: Aggrenox late-phase trial data in ischemic stroke
134 Table 32: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
137 Table 33: Plavix drug profile
139 Table 34: Plavix pivotal trial data in ischemic stroke
141 Table 35: Plavix ongoing late-phase clinical trials in ischemic stroke
147 Table 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
152 Table 37: Late-stage compounds that were recently discontinued for ischemic stroke
153 Table 38: Ampyra drug profile
154 Table 39: Ampyra late-phase trial data in ischemic stroke
155 Table 40: Brilinta drug profile
156 Table 41: Brilinta late-phase trial data in ischemic stroke
157 Table 42: Desmoteplase drug profile
158 Table 43: Desmoteplase late-phase trial data in ischemic stroke
159 Table 44: Xarelto drug profile
160 Table 45: Xarelto late-phase trial data in ischemic stroke